Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, prospective, non-randomized, multi-center/single-center, open-label,
phase I clinical study aimed at evaluating the efficacy and safety of Disitamab Vedotin in
combination with PD-1 as posterior line treatment for patients with advanced HER2-low
expressing gastric cancer.